» Articles » PMID: 37204672

Very Short-term Tissue Coverage of the CD34 Antibody-covered Sirolimus-eluting Stent: an Optical Coherence Tomography Study

Overview
Publisher Springer
Date 2023 May 19
PMID 37204672
Authors
Affiliations
Soon will be listed here.
Abstract

It is well known that patients with acute myocardial infarction (AMI) have delayed vessel healing despite accelerated endothelial progenitor cells (EPC) mobilization. The COMBO stent is a unique biodegradable-polymer sirolimus-eluting stent with an anti-CD34 antibody coating which captures EPC and potentially promotes vessel healing. However, there are limited data about strut tissue coverage at the very short-term period after COMBO stent implantation. This was a prospective study to investigate strut tissue coverage within 1 month after COMBO stent implantation using optical coherence tomography (OCT). Struts fully covered with tissue were defined as covered, and struts with distance from lumen surface longer than strut plus polymer thickness were defined as malapposed. Mean tissue thickness was measured only in apposed struts. A total of 8173 struts of 33 lesions in 32 patients were analyzed at an average of 19.8 ± 4.6 days after COMBO stent implantation. In lesion-level analysis, the rate of covered struts was 89.6 ± 7.2%, the rate of malapposed struts was 0.9 ± 2.0% and mean tissue thickness was 46.8 ± 14.3 µm. In comparison between AMI (n = 12) and non-AMI (n = 21) patients, there were no significant differences in the rate of covered struts (88.4 ± 8.4% vs. 90.2 ± 6.6%, p = 0.48) and mean tissue thickness (46.8 ± 13.7 µm vs. 46.9 ± 15.0 µm, p = 0.98). Multivariable analysis demonstrated that time from implantation to OCT imaging was significantly associated with mean tissue thickness. The COMBO stent had substantial tissue coverage at the very short-term period after implantation even in AMI patients, and follow-up time had an impact on vessel healing.

Citing Articles

Antithrombotic management in atrial fibrillation patients following percutaneous coronary intervention: A clinical review.

Saito Y, Kobayashi Y J Arrhythm. 2024; 40(5):1108-1114.

PMID: 39416245 PMC: 11474516. DOI: 10.1002/joa3.13128.

References
1.
Babapulle M, Joseph L, Belisle P, Brophy J, Eisenberg M . A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet. 2004; 364(9434):583-91. DOI: 10.1016/S0140-6736(04)16850-5. View

2.
Morice M, Serruys P, Sousa J, Fajadet J, Ban Hayashi E, Perin M . A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002; 346(23):1773-80. DOI: 10.1056/NEJMoa012843. View

3.
Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C . Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007; 369(9562):667-78. DOI: 10.1016/S0140-6736(07)60314-6. View

4.
Nakazawa G, Finn A, Joner M, Ladich E, Kutys R, Mont E . Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation. 2008; 118(11):1138-45. DOI: 10.1161/CIRCULATIONAHA.107.762047. View

5.
Takano M, Inami S, Jang I, Yamamoto M, Murakami D, Seimiya K . Evaluation by optical coherence tomography of neointimal coverage of sirolimus-eluting stent three months after implantation. Am J Cardiol. 2007; 99(8):1033-8. DOI: 10.1016/j.amjcard.2006.11.068. View